A contraindication is a fundamental reason a person should not use the peptide at all due to a pre-existing condition (e.g., a copper disorder)
While some studies suggest glutathione precursors like N-acetylcysteine (NAC) increase intracellular glutathione, oral glutathione itself has poor bioavailability due to rapid degradation
GHRH itself was characterized in the early 1980s, isolated originally from pancreatic tumors in patients with acromegaly and shown to consist of a 44-residue amidated peptide (and shorter active derivatives)
Studies are still ongoing regarding the precise means by which exogenous NAD+ supplementation exerts these effects
Much of this tracking stems from wellness blogs, Reddit forums, peptide clinics, and social media
This means IV administration delivers more active glutathione into the bloodstream, typically producing faster and more consistent results